Navigation Links
Key growth factor identified in T cell leukemia
Date:8/1/2011

Blocking a growth factor receptor cripples cancer growth in a form of T cell leukemia, according to a study published online on August 1 in the Journal of Experimental Medicine (www.jem.org).

Approximately half of the cases of T cell acute lymphoblastic leukemia (T-ALL) carry genetic mutations in a cellular signaling pathway called Notch, which result in aberrant activation of the cell. A study by Andrew Weng and colleagues at the British Columbia Cancer Agency now shows that activation of the Notch pathway promotes the expression of a receptor for insulin growth factor (IGF-1), which drives the growth and survival of the cancer cells.

Cancer cells with an activated Notch pathway but lacking the IGF-1 receptor had reduced growth in mice, and blocking the receptor with drugs improved their survival. Simply reducing the amount of receptor resulted in the loss of cancer stem cellsthe cells responsible for originating and perpetuating the disease. Human T-ALL cells were also found to express IGF-1 receptor, suggesting that blocking the receptor in combination with standard treatment may reduce the risk of disease relapse.


'/>"/>

Contact: Rita Sullivan
news@rupress.org
212-327-8603
Rockefeller University Press
Source:Eurekalert

Page: 1

Related medicine news :

1. Education -- a key determinant of population growth and human well-being
2. Progesterone inhibits growth of neuroblastoma cancer cells
3. Self-referral: A significant factor in imaging growth
4. Hereditary colon cancer syndrome marked by abnormally dense blood vessel growth in mouth
5. Slow growth of childhood brain tumors linked to genetic process seen in skin moles
6. Scientists image beginning stages of ovarian cancer growth with time-lapse technique
7. Cancer cells accelerate aging and inflammation in the body to drive tumor growth
8. Common transplant drug inhibits breast cancer growth, UNC laboratory study shows
9. Enzyme may drive breast cancer growth
10. Artificial tissue promotes skin growth in wounds
11. Obstructive sleep apnea linked to cancer growth in mice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... July 21, 2017 , ... ... students improve their chances of acceptance to a residency in a United States ... earned degrees outside the U.S. , According to data released by the ECFMG®, ...
(Date:7/21/2017)... ... July 21, 2017 , ... West Dermatology is pleased ... Vu, PA-C. Beginning July 17, 2017, Ms. Vu will join West Dermatology’s large network ... experience in dermatology, skin cancer , and more. She graduated from the University ...
(Date:7/21/2017)... ... July 21, 2017 , ... How physicians and ... the rise, say researchers presenting their work at the American Orthopaedic Society ... combination of evaluating the patterns of change in concussion symptom presentation, diagnostic tools ...
(Date:7/20/2017)... ... July 20, 2017 , ... Acute myeloid leukemia (AML) is ... rapidly without treatment. Newly diagnosed patients face intense chemotherapy regimens and a stem ... With such a challenging diagnosis that requires immediate action, patients and caregivers ...
(Date:7/20/2017)... ... ... For individuals with extended hospital stays or who are residents of nursing ... specially designed to accommodate patients with a wide range of ailments or special needs, ... has invented the patent-pending PORTABLE ARM REST, a specially designed armrest that features many ...
Breaking Medicine News(10 mins):
(Date:7/12/2017)... and Company (NYSE: LLY ) has entered into ... litigation in the U.S. District Court for the Eastern District ... (tadalafil) unit dose patent. This patent was previously set ... agreement, Cialis exclusivity is now expected to end at the ... patent for Cialis is valid and infringed by companies seeking ...
(Date:7/11/2017)... 11, 2017  The global market for liquid biopsy ... $394.1 million in 2016.  Although in early stages, the ... in particular as a result of the gradual shift ... recent introduction of a significant number of new liquid ... of tumor biomarkers to guide treatment decisions. ...
(Date:7/11/2017)... July 11, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral drug ... Drug Administration (FDA) has agreed to schedule an End-of-Phase ... IIb trial of its oral insulin capsule ORMD-0801 in ... trial met primary and secondary endpoints by indicating a ...
Breaking Medicine Technology: